Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ghazaleh Bigdeli

Critical Care Medicine Youngstown, OH Medical Doctor

NPI 1003806134 CMS profile 181628

925 Trailwood Dr, Youngstown, OH 44512

Open in the dashboard

General payments

$10,268

339 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ghazaleh Bigdeli of Youngstown, OH is reported in the CMS Open Payments database as having received $10,268 across 339 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,260 58
2024 General $1,646 57
2023 General $3,714 59
2022 General $1,005 53
2021 General $663 29
2020 General $678 37
2019 General $1,302 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ghazaleh Bigdeli
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Ghazaleh Bigdeli were reported at $1,260. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Ghazaleh Bigdeli Critical Care Medicine median Middle half National median
2019 $1,302 $149 $51–$535 $163
2020 $678 $110 $30–$325 $114
2021 $663 $125 $34–$403 $132
2022 $1,005 $157 $49–$582 $149
2023 $3,714 $162 $56–$621 $160
2024 $1,646 $168 $53–$634 $164
2025 $1,260 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Noah Medical Corporation $2,451 13 payments
  2. AstraZeneca Pharmaceuticals LP $1,713 65 payments
  3. GlaxoSmithKline, LLC. $1,058 81 payments
  4. Regeneron Healthcare Solutions, Inc. $453 17 payments
  5. United Therapeutics Corporation $446 11 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $391 18 payments
  7. Genzyme Corporation $327 10 payments
  8. Jazz Pharmaceuticals Inc. $259 7 payments
  9. Merck Sharp & Dohme Corporation $255 9 payments
  10. Amgen Inc. $247 9 payments
  11. Other $2,668 99 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,630 322 payments
  2. Travel and Lodging $2,503 11 payments
  3. Education $134 6 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE Respiratory $405 12 payments
  2. TRELEGY ELLIPTA $398 29 payments
  3. OFEV $323 19 payments
  4. AIRSUPRA $301 10 payments
  5. FASENRA Respiratory $291 16 payments
  6. DUPIXENT $288 11 payments
  7. FASENRA Respiratory $286 4 payments
  8. TEZSPIRE Inflammation $247 9 payments
  9. XYWAV $244 6 payments
  10. ZERBAXA $235 8 payments
  11. Other $6,216 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,682

Median for Internal Medicine: 777

Drug cost

$838,229

Median for Internal Medicine: $73,373

Branded share of claims

72.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 312 $240,994
Ofev Nintedanib Esylate Brand 21 $172,938
Nucala Mepolizumab Brand 31 $124,536
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 89 $59,615
Breo Ellipta Fluticasone/Vilanterol Brand 121 $54,817
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 85 $48,045
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 51 $26,172
Spiriva Respimat Tiotropium Bromide Brand 27 $18,338
Advair Hfa Fluticasone Propion/Salmeterol Brand 11 $10,881
Dulera Mometasone/Formoterol Brand 21 $10,408

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$138,027

Of which drugs: $956

Medicare patients

520

Average age 75

Services billed

1,633

294 women, 226 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
COPD 56%
Diabetes 49%
Heart failure 46%
Ischemic heart disease 44%
Chronic kidney disease 43%
Atrial fibrillation 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $181
  • Amgen Inc. $58
$238 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $153
$153 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $119
$119 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $77
  • GENZYME CORPORATION $28
$104 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $60
  • Genentech USA, Inc. $23
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

339 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record